The Scanly Home OCT by Notal Vision is the first at-home OCT imaging device to hit the market. Photo: Notal Vision. Click image to enlarge.

Patients with neovascular AMD are often subject to frequent office visits so that eyecare providers can monitor anatomical changes and signs of disease progression on OCT—but what if physicians could perform this imaging remotely? This is now possible with the recent FDA approval of the first at-home OCT from Notal Vision, marketed as “Scanly,” which uses artificial intelligence software to evaluate various imaging biomarkers in nAMD. By analyzing scans remotely between scheduled visits, eye doctors may be able to gain additional insight into patients’ disease status, while also cutting back on their travel time.

The company explains in its press release that the device captures spectral-domain OCT images in a 10x10-degree area centered on the point of fixation. Once scans are complete, the AI software is used to segment and estimate the volume of hypo-reflective spaces. All images are automatically transmitted via a built-in wireless connection and stored in the Notal Health Cloud for analysis. There, physicians can review data and set eye-specific notification criteria (including a volume threshold for total retinal hypo-reflective spaces), as well as receive notifications via a web portal.

Two pivotal US trials involving more than 500 patients with nAMD (mean age: 77) were completed to assess the accuracy and user-friendliness of the home OCT device. Notal Vision reports that 97% of the total 5,426 scans performed by patients in the study eye were successful. The company further noted an adherence rate of 5.9 scans/week, and on average, patients took 48 seconds to self-image.

To have a Scanly Home OCT device shipped to a patient’s home, the patient must first enroll in what Notal Vision calls the “Scanly Home OCT Monitoring Program.” For more information on the program or device itself, go to notalvision.com/services/scanly-oct.